Navigation Links
Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
Date:10/23/2007

LONDON, Oct. 23 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced the initiation of a Phase I tolerance study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).

The randomized, placebo-controlled, double blind clinical trial is the first of two modules focusing on safety for Morria's first human study in AR. MRX-4 is nasally administered as a single dose either with or without an allergen challenge to determine tolerance. Results are expected by the end of the fourth quarter of 2007.

"We are excited to be taking this significant step toward introducing a potentially safer, more effective and more affordable treatment option to the multibillion-dollar AR market," said Yuval Cohen Ph.D., President of Morria.

"There is a real and urgent need for novel, non-steroidal treatments for inflammatory diseases such as allergic rhinitis. Morria's drug platform could potentially offer such an alternative," said Peter Barnes, a professor at the National Heart & Lung Institute at Imperial College in London and Morria scientific advisory board member.

ABOUT ALLERGIC RHINITIS

Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of nearly $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.

ABOUT MORRIA BIOPHARMACEUTICALS Plc

Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals known as multi-functional anti-inflammatory drugs (MFAIDs). This class of drugs uniquely combines two promising approaches to preventing and reversing inflammation: first, they control the phospholipase A2 (PLA2) enzyme family, a known but previous
'/>"/>

SOURCE Morria Biopharmaceuticals Plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
3. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
6. Malvern initiates European user group meetings for chemical imaging
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014  Mark Riccio, director of Cornell ... is using the online crowd-funding platform Kickstarter to ... to researchers and would-be superheros everywhere: "for FREE." ... YOU do if you had Superman,s X-ray vision?" ... explorers everywhere, from elementary through high school students, ...
(Date:8/22/2014)... 22, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today ... units of common stock and warrants at a price ... million, prior to deducting underwriting discounts and commissions and ... warrants are immediately separable and will be issued separately.  ... trading on The NASDAQ Stock Market under the ticker ...
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ( ... announced today that it has completed integration with ... for Plastic Surgery and Dermatology practices. ... value to healthcare practices using Nextech," stated ... Corporation. "Using information from the EMR we are ...
Breaking Medicine Technology:Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
(Date:8/22/2014)... 2014 As the controversy surrounding ... in uterine surgeries continues to grow, Bernstein Liebhard ... decided to limit coverage of uterine morcellation. According ... Cross-Blue Shield of Massachusetts will no longer cover ... as of September 1, 2014. Other insurers in ...
(Date:8/22/2014)... Bcl-2-like protein 11 (BIM) deletion in advanced non-small ... progression free survival (PFS) in epidermal growth factor ... treated Asian patients. Also, BIM deletion independently predicts ... The BIM protein can activate the programmed cell ... cells. BIM deletion has been detected in 12.8% ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... by Dr. Sen and Dr. Samantha Pearson to help ... contacts, and avoid corrective vision surgery by instead improving ... Michaels, prompting an investigative review. , “There’s a ... of dollars in revenue each year—it’s because people just ...
(Date:8/22/2014)... CarePoint Health is proud to ... Geriatrics, Hospice and Palliative Care, Dr. Michelle Reisner, ... Their system welcomes Dr. Reisner to the community. ... CarePoint Health Medical Group, a comprehensive network of ... a wide range of specialties. This latest acquisition ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Dayton Children's Hospital ... tower as part of a $141 million campus renewal. ... care tower were unveiled to the public. , The ... plan that will create a campus that meets the needs ... These new care spaces will embody Dayton Children’s unique patient ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5
... Strength and Conditioning Coach Greg Brittenham Rally Students to Get ... Fit Grant NEW YORK, March 19 New York Knicks ... Brittenham are rallying New York City teens to get teenagers ... campaign called Get Fit By Finals . The ...
... Lawsuit Alleges that Drywall Emits Toxins Harmful to Humans ... Jason and Melissa Harrell recently filed a class ... of themselves and other homeowners who purchased defective homes. ... new home, and those of their neighbors, emits destructive ...
... Va., March 19 Together Rx Access(R), a prescription ... pharmaceutical companies, announced today that it has expanded the ... individuals and families save on the medicines they need ... the new income levels, nearly 90 percent of uninsured ...
... of Anesthesiologists, Action vs. RhetoricCORONA DEL MAR, Calif., March ... very fair odds. Yet, that,s exactly what the foremost ... set the stage for last week when he responded ... press release in which they claimed to be in ...
... by the American Society for Aesthetic Plastic Surgery, the number of cosmetic ... this sharp decline nationally, the flow of patients at the Center for ... , ... Annandale VA (Vocus) March 19, 2009 -- The ASAPS data ...
... been waiting on for the past four years to prove the deposition ... ... March 19, 2009 -- Most ENT,s and physicians have prescribed Sinus ... a clinical study done on the amount of medication deposited and penetrated ...
Cached Medicine News:Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Democracy Prep Charter School 2Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Democracy Prep Charter School 3Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Democracy Prep Charter School 4Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Democracy Prep Charter School 5Health News:Class Action Filed Against South Florida Developer and Supplier of Defective Chinese Drywall 2Health News:Class Action Filed Against South Florida Developer and Supplier of Defective Chinese Drywall 3Health News:Together Rx Access(R) Program Expands Eligibility Criteria, Responds to Challenging Economic Times 2Health News:Together Rx Access(R) Program Expands Eligibility Criteria, Responds to Challenging Economic Times 3Health News:Together Rx Access(R) Program Expands Eligibility Criteria, Responds to Challenging Economic Times 4Health News:Dr. Barry Friedberg comments on David vs. Goliath: Who's Really in the Pursuit of Patient Safety & Satisfaction? 2Health News:The Center for Plastic Surgery in Washington, DC Survives the Economy Despite Nationwide Data Reported by ASAPS 2Health News:New Clinical Study News for Treatment of Sinusitis - Sinus Infection and Allergy Suffers Now Have a New Effective Form of Relief through Sinus Dynamics 2Health News:New Clinical Study News for Treatment of Sinusitis - Sinus Infection and Allergy Suffers Now Have a New Effective Form of Relief through Sinus Dynamics 3Health News:New Clinical Study News for Treatment of Sinusitis - Sinus Infection and Allergy Suffers Now Have a New Effective Form of Relief through Sinus Dynamics 4
Thompson surgical radiotranslucent anterior lumbar retractor system....
... is the first true high-speed, high-torque touch control ... comparable to Legend Gold and runs at 73,000 ... design provides ergonomic positioning and true variable speed ... the Legend Gold Touch is also smaller, with ...
... The METRx Microdiscectomy System incorporates specially designed ... a surgical area in a minimally invasive ... diameter size from 5.3 mm to 20.8 ... inserted sequentially - one around the other ...
... System, a uniquely designed system combining ... two systems into one. Detachable blade ... site during retractor placement, providing better ... retractor body slides easily onto the ...
Medicine Products: